KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$48.8 million.

  • Nektar Therapeutics' Cash from Operations fell 1099.2% to -$48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189.7 million, marking a year-over-year decrease of 745.88%. This contributed to the annual value of -$175.7 million for FY2024, which is 877.28% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Cash from Operations stood at -$48.8 million, which was down 1099.2% from -$45.7 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Cash from Operations high stood at -$37.7 million for Q2 2024, and its period low was -$151.5 million during Q4 2021.
  • Its 5-year average for Cash from Operations is -$64.7 million, with a median of -$51.5 million in 2023.
  • In the last 5 years, Nektar Therapeutics' Cash from Operations plummeted by 9200.0% in 2021 and then skyrocketed by 6192.18% in 2022.
  • Over the past 5 years, Nektar Therapeutics' Cash from Operations (Quarter) stood at -$151.5 million in 2021, then surged by 61.92% to -$57.7 million in 2022, then rose by 18.47% to -$47.0 million in 2023, then increased by 1.83% to -$46.2 million in 2024, then fell by 5.57% to -$48.8 million in 2025.
  • Its last three reported values are -$48.8 million in Q3 2025, -$45.7 million for Q2 2025, and -$49.1 million during Q1 2025.